CGHS maps domestic manufacturing capacity for 153 critical drugs to reduce supply delays | Today’s news
To expedite drug procurement, the CGHS has directed drug manufacturers and authorized importers to submit regulatory and manufacturing applications for oncology, diabetes, spinal muscular atrophy therapy and bispecific antibodies.
